[Cholesterol absorption as a target for the treatment of hypercholesterolemia].
Harefuah
; 145(11): 831-5, 861, 860, 2006 Nov.
Article
em He
| MEDLINE
| ID: mdl-17183957
ABSTRACT
Hypercholesterolemia is a major risk factor for atherosclerosis. HMG-CoA Reductase inhibitors (statins), which block hepatic synthesis of cholesterol, are the mainstay of therapy of hypercholesterolemia. Recent trials have demonstrated the importance of maintaining very low LDL-cholesterol levels in high-risk patients. Such low levels are sometimes hard to reach with statin monotherapy. Another source of cholesterol is intestinal absorption of dietary cholesterol and bile salts. Recent studies have elucidated the mechanism of intestinal cholesterol absorption. Ezetimibe, a specific inhibitor of cholesterol absorption can be used as an add-on therapy to statins in order to achieve treatment goals.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Colesterol na Dieta
/
Hipercolesterolemia
/
Absorção Intestinal
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
He
Revista:
Harefuah
Ano de publicação:
2006
Tipo de documento:
Article